Mechanisms of thrombosis in cancer

Thrombosis Research

Volumn 115, Issue SUPPL., 2005, Pages 21-24

  Falanga, A ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; CANCER PROCOAGULANT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN; VON WILLEBRAND FACTOR;

BLOOD VESSEL WALL; CANCER; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; HOST RESISTANCE; HUMAN; LIVER TOXICITY; MACROPHAGE; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBOSIS; TUMOR CELL; VASCULAR ENDOTHELIUM;

BLOOD COAGULATION FACTORS; CELL COMMUNICATION; CYTOKINES; ENDOTHELIUM, VASCULAR; FEMALE; HEMOSTASIS; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 12544259686     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62:14-31.
2. Rickles FR, Levine MN, Edwards RL. Hemostatic alterations in cancer patients. Cancer Met Rev 1992;11:237-48.
3. Falanga A, Barbui T, Rickles FR, Levine MN. Guidelines for clotting studies in cancer patients. Thromb. Haemost 1993;70:343-50.
4. Donati MB, Poggi A, Semeraro N. Coagulation and malignancy. Recent Advances in Blood Coagulation. In: Poller L, editor. Churchill Livingstone; 1981. p. 227-59.
5. Gadducci A, Baicchi U, Marrai R, Del Bravo B, Fosella PV, Facchini V. Pretreatment plasma levels of fibrinopeptide A (FPA), DDimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynec Oncol 1994;53:352-6.
6. Catani L, Gugliotta L, Vianelli N, et al. Endothelium and bone marrow transplantation. Bone Marrow Transpl 1996;17:277-80.
7. Semeraro N, Montemurro P, Conese M, et al. Procoagulant activity of mononuclear phagocytes from different anatomical sites in patients with gynaecological malignancies. Int J Cancer 1990;45:251-4.
8. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991;61:271-8.
9. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with Essential Thrombocythemia and Polycythemia Vera. Blood 2000;96:4261-6.
10. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone Jr MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Pro Natl Acad Sci USA 1986;83:4533-7.
11. Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159-65.
12. Van Hinsberg VWM, Bauer KA, Kooistra T, et al. Progress of fibrinolysis during tumor necrosis factor infusion in humans. Concomitant increase of tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. Blood 1990;76:2284-9.
13. Honn KV, Tang DG, Chen YQ. Adhesion molecules and site-specific metastases. In: Neri Serneri GG, Abbate R, Gensini G, Prisco D, editors. Thrombosis an Update. Scientific Press Florence; 1992. p. 269-303.
14. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Medicine 1996;2:209-15.
15. Al-Mondhiry H. Betathromboglobulin and platelet factor 4 in patients with cancer. Correlation with the stage of disease and the effect of chemotherapy. Am J Hematol 1983;14:105-11.
16. Wehmeier A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991;61:271-8.
17. Gasic GJ, Gasic TB. Plasma membrane vescicles as mediators of interactions between tumor cells and components of the hemostatic and immune system. In: Jamieson GA, Liss Alan R, editors. Interactions of platelets and tumor cells. New York; 1982. p. 429.
18. Grignani G, Jamieson GA. Platelets in tumor metastasis: generation of ADP by tumor cells is specific but not unrelated to metastatic potential. Blood 1988;71:844-9.
19. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997;78:759-64.
20. Lorenzet R, Peri G, Locati D, et al. Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissue. Blood 1983;62:2721-3.
21. Gordon SG. Tumor cell procoagulants and their role in malignant disease. Sem Thromb Haemost 1992;18:424-33.
22. Nemerson Y. The tissue factor pathway of blood coagulation. Sem Hematol 1992;29:170-6.
23. Gordon SG, Cross BA. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as new tumor marker. Cancer Res 1990;50:6229-34.
24. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-Retinoic Acid. Blood 1995;86:1072-84.
25. Barbui T, Finazzi G, and Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998;91:3093-102.
26. Kwaan HC, Keet HN. Fibrinolysis and cancer. Semin Thromb Haemost 1990;16:230.
27. Rocha E, Pàramo JA, Fernàndez FJ, et al. Clotting activation and impairment of fibrinolysis in malignancy. Thromb Res 189;54:699-707.
28. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Nat Acad Sci (USA) 1999;96:8663-8.
29. Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997;7:52-9.
30. Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Expl Metastasis 1990;8:511-8.
31. Walsh J, Wheeler HR, Geczy CL. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992;81:480-8.
32. Harper PL, Jarvis J, Jennings I, Luddington R, Marcus RE. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transpl 1990;5:39-42.